Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients

AIDS

Volumn 30, Issue 17, 2016, Pages 2635-2643

  Vuille Lessard, Élise ^a   Lebouché, Bertrand ^a   Lennox, Lynda ^a   Routy, Jean Pierre ^a   Costiniuk, Cecilia T ^a   Pexos, Costa ^a   Giannakis, Andreas ^a   Szabo, Jason ^a   Klein, Marina B ^a   Sebastiani, Giada ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Controlled attenuation parameter; Diabetes; Elevated alanine aminotransferase; HIV monoinfection; Liver fibrosis; Nonalcoholic fatty liver disease; Overweight; Transient elastography

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR;

ADULT; ANTIRETROVIRAL THERAPY; ARTICLE; BODY MASS; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIAGNOSTIC IMAGING; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PREDICTOR VARIABLE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSIENT ELASTOGRAPHY; COMPLICATION; ELASTOGRAPHY; MIDDLE AGED;

ADULT; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROSPECTIVE STUDIES;

EID: 84986201496     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000001241     Document Type: Article

References (39)

1. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D: A: D study. Arch Intern Med 2006; 166: 1632-1641.
2. Lemoine M, Serfaty L, Capeau J. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: Diagnosis and management. Curr Opin Infect Dis 2012; 25: 10-16.
3. Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. Semin Liver Dis 2012; 32: 103-113.
4. Crum-Cianflone N, Collins G, Medina S, Asher D, Campin R, Bavaro M, et al. Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons. Clin Gastroenterol Hepatol 2010; 8: 183-191.
5. Nix LM, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep 2014; 11: 271-278.
6. Rockstroh JK, Mohr R, Behrens G, Spengler U. Liver fibrosis in HIV: Which role does HIV itself, long-term drug toxicities and metabolic changes play? Curr Opin HIV AIDS 2014; 9: 365-370.
7. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
8. Sterling RK, Smith PG, Brunt EM. Hepatic steatosis in human immunodeficiency virus: A prospective study in patients without viral hepatitis, diabetes, or alcohol abuse. J Clin Gastroenterol 2013; 47: 182-187.
9. Crum-CianfloneN,DilayA,CollinsG,AsherD,CampinR,Medina S, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50: 464-473.
10. DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V 3rd. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis 2010; 10: 116.
11. Price JC, Seaberg EC, Badri S, Witt MD, D'Acunto K, Thio CL. HIV monoinfection is associated with increased aspartate aminotransferase-to-platelet ratio index, a surrogate marker for hepatic fibrosis. J Infect Dis 2012; 205: 1005-1013.
12. Stabinski L, Reynolds SJ, Ocama P, Laeyendecker O, Ndyanabo A, Kiggundu V, et al. High prevalence of liver fibrosis associated with HIV infection: A study in rural Rakai, Uganda. Antivir Ther 2011; 16: 405-411.
13. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver Diseases. Liver biopsy. Hepatology 2009; 49: 1017-1044.
14. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: The diagnosis and staging of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Aliment Pharmacol Ther 2011; 33: 525-540.
15. Chang PE, Goh GB, Ngu JH, Tan HK, Tan CK. Clinical applications, limitations and future role of transient elastography in the management of liver disease. World J Gastrointest Pharmacol Ther 2016; 7: 91-106.
16. Macias J,Gonzalez J,Tural C,Ortega-Gonzalez E,PulidoF,Rubio R, et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS 2014; 28: 1279-1287.
17. Morse CG, McLaughlin M, Proschan M, Koh C, Kleiner DE, Heller T, et al. Transient elastography for the detection of hepatic fibrosis in HIV-monoinfected adults with elevated aminotransferases on antiretroviral therapy. AIDS 2015; 29: 2297-2302.
18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
19. Roulot D, Costes JL, Buyck JF, Warzocha U, Gambier N, Czernichow S, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60: 977-984.
20. Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, et al. Performance of transient elastography for the staging of liver fibrosis: A meta-analysis. Gastroenterology 2008; 134: 960-974.
21. Yatsuji S, Hashimoto E, Tobari M, Taniai M, Tokushige K, Shiratori K. Clinical features and outcomes of cirrhosis due to nonalcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 2009; 24: 248-254.
22. Ryan P, Blanco F, Garcia-Gasco P, Garcia-Merchan J, Vispo E, Barreiro P, et al. Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. HIV Med 2009; 10: 53-59.
23. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-1302.e4.
24. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-1112.
25. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014; 104: 1-52.
26. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. Audit. The Alcohol Use Disorders Identification Test (AUDIT): Guidelines for use in primary care.2001.
27. Cohen J. Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull 1968; 70: 213-220.
28. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIVinfected patients referred to a metabolic clinic: Prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47: 250-257.
29. Sulyok M, Makara M, Rupnik Z, Ferenci T, Ujhelyi E, Kormos L, et al. Hepatic steatosis in individuals living with HIV measured by controlled attenuation parameter: A cross-sectional study. Eur J Gastroenterol Hepatol 2015; 27: 679-685.
30. Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: A case-control study. Aliment Pharmacol Ther 2015; 41: 368-378.
31. Hasson H, Merli M, Galli L, Gallotta G, Carbone A, Messina E, et al. Noninvasive fibrosis biomarkers - APRI and Forns - Are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. Liver Int 2013; 33: 1113-1120.
32. Sebastiani G, Rollet-Kurhajec KC, Pexos C, Gilmore N, Klein MB. Incidence and predictors of hepatic steatosis and fibrosis by serum biomarkers in a large cohort of human immunodeficiency virus mono-infected patients. Open Forum Infect Dis 2015; 2: Ofv015.
33. Morse CG, McLaughlin M, Matthews L, Proschan M, Thomas F, Gharib AM, et al. Nonalcoholic steatohepatitis and hepatic fibrosis in HIV-1-monoinfected adults with elevated aminotransferase levels on antiretroviral therapy. Clin Infect Dis 2015; 60: 1569-1578.
34. Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179-1184.
35. Pelletier C, Dai S, Roberts KC, Bienek A, Onysko J, Pelletier L. Report summary. Diabetes in Canada: Facts and figures from a public health perspective. Chronic Dis Inj Can 2012; 33: 53-54.
36. Haukeland JW, Konopski Z, Linnestad P, Azimy S, Marit Loberg E, Haaland T, et al. Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol 2005; 40: 1469-1477.
37. Nunez M. Clinical syndromes and consequences of antiretroviral- related hepatotoxicity. Hepatology 2010; 52: 1143-1155.
38. Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. J Investig Med 2014; 62: 920-926.
39. El-Serag HB, Kramer J, Duan Z, Kanwal F. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol 2014; 109: 1427-1435.